A species of bacterium with high chitosanase activity was isolated from soil samples in Haiyan City, China, and identified as an Acinetobacter species. This strain, named Acinetobacter sp. strain C-17, produced a chitosanase that was inducible and secreted into the medium. The optimal conditions for enzyme production were cells used to inoculate a medium containing 1% chitosan (pH 7.0) followed by culture at 30 degrees C. The chitosanase activity reached 1.7 U/ml when strain C-17 was incubated in a 250-ml flask under the optimal conditions for 24 h, and reached 2.8 U/ml when cells were incubated in a 3-l fermentor. The optimal pH and temperature for hydrolysis of chitosanase were 7.0 and 36 degrees C, respectively. The chitosanase activity was stable in the pH range of 5-8 and temperature range of 30-40 degrees C. The chitosanase of the strain was extracted by zinc acetate and ammonium sulfate precipitation. The molecular mass was estimated to be 35.4 kDa by SDS-PAGE.

Human complement receptor 1 (HuCR1) is a pivotal regulator of complement activity, acting on all three complement pathways as a membrane-bound receptor of C3b/C4b, C3/C5 convertase decay accelerator, and cofactor for factor I-mediated cleavage of C3b and C4b. In this study, we sought to identify a minimal soluble fragment of HuCR1, which retains the complement regulatory activity of the wildtype protein. To this end, we generated recombinant, soluble, and truncated versions of HuCR1 and compared their ability to inhibit complement activation in vitro using multiple assays. A soluble form of HuCR1, truncated at amino acid 1392 and designated CSL040, was found to be a more potent inhibitor than all other truncation variants tested. CSL040 retained its affinity to both C3b and C4b as well as its cleavage and decay acceleration activity and was found to be stable under a range of buffer conditions. Pharmacokinetic studies in mice demonstrated that the level of sialylation is a major determinant of CSL040 clearance in vivo . CSL040 also showed an improved pharmacokinetic profile compared with the full extracellular domain of HuCR1. The in vivo effects of CSL040 on acute complement-mediated kidney damage were tested in an attenuated passive antiglomerular basement membrane antibody-induced glomerulonephritis model. In this model, CSL040 at 20 and 60 mg/kg significantly attenuated kidney damage at 24 h, with significant reductions in cellular infiltrates and urine albumin, consistent with protection from kidney damage. CSL040 thus represents a potential therapeutic candidate for the treatment of complement-mediated disorders.

One of the primary goals of traditional livestock breeding is to improve growth rate and optimise body size. Growth rate can be significantly increased by integrating a growth hormone (GH) transgene under the control of a ubiquitous promoter, but while such animals do demonstrate increased growth there are also serious deleterious side-effects to the animals health. Here we report the generation and initial characterization of transgenic mice that carried a porcine BAC encoding the porcine GH gene. We show that GH expression is restricted specifically to the pituitary, is associated with elevated IGF-1 levels, and results in growth enhancement. No negative effects to the health of the transgenic animals were detected. This initial characterisation supports the use of BAC pGH transgene in livestock studies.

No abstract